Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer

Cancer

Volumn 116, Issue 22, 2010, Pages 5251-5260

  Hess, Lisa M ^a,b   Rong, Nan ^a   Monahan, Patrick O ^a,b   Gupta, Paridha ^a   Thomaskutty, Champ ^a   Matei, Daniela ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy; consolidation; maintenance; meta analysis; ovarian cancer

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; OREGOVOMAB; PACLITAXEL; TOPOTECAN; YTTRIUM 90;

ABDOMEN; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; FEMALE; HAZARD RATIO; HUMAN; HYPERTHERMIC THERAPY; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RECURRENCE RISK; REMISSION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 78449296942     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25487     Document Type: Article

References (57)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Huang L, Cronin KA, Johnson KA, et al. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer ? Cancer. 2008; 112: 2289-2300.
3. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer. J Clin Oncol. 1997; 15: 193-198.
4. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998; 16: 2426-2434.
5. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer. J Clin Oncol. 2009; 27: 1419-1425.
6. Alberts DS, Hannigan EV, Liu PY, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy. Gynecol Oncol. 2006; 100: 133-138.
7. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. J Clin Oncol. 2003; 21: 2460-2465.
8. De, Placido S, Scambia G, Di, Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer. J Clin Oncol. 2004; 22: 2635-2642.
9. Cassileth PA, Begg CB, Bennett JM, et al. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood. 1984; 63: 843-847.
10. Sauter C, Berchtold W, Fopp M, et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984; 1: 379-382.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100: 3983-3988.
12. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68: 4311-4320.
13. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel. Gynecol Oncol. 2009; 114: 195-198.
14. Micha JP, Goldstein BH, Graham C, et al. Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology. 2006; 71: 49-53.
15. Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus 6 courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after 6 courses of paclitaxel/platinum-based chemotherapy. J Clin Oncol. 2009; 27: 4642-4648.
16. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT., The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol. 2006; 102: 218-225.
17. Foster T, Brown TM, Chang J, et al. A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol. 2009; 115: 290-301.
18. McGuire WP., Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol. 2009; 27: 4633-4634.
19. Cho MK, Bero LA., Instruments for assessing the quality of drug studies published in the medical literature. JAMA. 1994; 272: 101-104.
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
21. Lipsey MW, Wilson, D.B., Practical Meta-Analysis. Thousand Oaks, CA: Sage Publications; 2001.
22. Persaud R., Misleading meta-analysis. "Fail safe N" is a useful mathematical measure of the stability of results. BMJ. 1996; 312: 125.
23. Duval S, Tweedie R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56: 455-463.
24. Cohn LD, Becker BJ., How meta-analysis increases statistical power. Psychol Methods. 2003; 8: 243-253.
25. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2010; 28: Abstract LBA 1.
26. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of 3 versus 6 cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma. Gynecol Oncol. 2006; 102: 432-439.
27. Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998; 69: 17-22.
28. Ben-Baruch G, Menczer J, Feldman B, Rizel S, Brenner H., Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. Eur J Gynaecol Oncol. 1994; 15: 272-276.
29. Menczer J, Ben-Baruch G, Modan M, Brenner H., Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Cancer. 1989; 63: 1509-1513.
30. Bolis G, Danese S, Tateo S, et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2006; 16 (suppl 1): 74-78.
31. Bruzzone M, Repetto L, Chiara S, et al. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol. 1990; 38: 392-395.
32. Goldberg H, Stein ME, Steiner M, Sprecher E, Beck D, Kuten A., Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma. Tumori. 2001; 87: 248-251.
33. Goldhirsch A, Greiner R, Dreher E, et al. Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer. 1988; 62: 40-47.
34. Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005; 15: 233-239.
35. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE., A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer. J Clin Oncol. 1993; 11: 440-448.
36. Lee SJ, Lee JW, Min JA, et al. A pilot study of 3-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. Int J Gynecol Cancer. 2006; 16: 95-100.
37. Menczer J, Ben-Baruch G, Rizel S, Brenner H., Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission. Cancer. 1992; 70: 1956-1959.
38. Nicholson S, Gooden CS, Hird V, et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep. 1998; 5: 223-226.
39. Nicoletto MO, Tumolo S, Falci C, et al. A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission? Int J Med Sci. 2004; 1: 116-125.
40. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007; 120: 2710-2714.
41. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006; 24: 571-578.
42. Papadimitriou C, Dafni U, Anagnostopoulos A, et al. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer. Bone Marrow Transplant. 2008; 41: 547-554.
43. Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875. Int J Gynecol Cancer. 2003; 13 (suppl 2): 196-203.
44. Pickel H, Lahousen M, Petru E, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol. 1999; 72: 215-219.
45. Pickel H, Petru E, Lahousen M, et al. Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Am J Clin Oncol. 1991; 14: 184-187.
46. Sorbe B., Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer. 2003; 13 (suppl 2): 192-195.
47. Sorbe B., Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial. Int J Gynecol Cancer. 2003; 13: 278-286.
48. Varia MA, Stehman FB, Bundy BN, et al. Intraperitoneal radioactive phosphorus versus observation after negative second-look laparotomy for stage III ovarian carcinoma. J Clin Oncol. 2003; 21: 2849-2855.
49. Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009; 27: 418-425.
50. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004; 22: 3507-3516.
51. Berek JS, Taylor PT, Nicodemus CF., CA125 velocity at relapse is a highly significant predictor of survival post relapse. J Immunother. 2008; 31: 207-214.
52. Hall GD, Brown JM, Coleman RE, et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004; 91: 621-626.
53. Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy. Gynecol Oncol. 2006; 102: 300-308.
54. Lawton F, Luesley D, Blackledge G, et al. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. Clin Oncol (R Coll Radiol). 1990; 2: 4-9.
55. Micha JP, Goldstein BH, Rettenmaier MA, et al. Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer. 2009; 19: 239-241.
56. Micha JP, Goldstein BH, Mattison JA, et al. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol. 2005; 96: 132-135.
57. Umesaki N, Tanaka T, Muso H, et al. Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission. Gynecol Obstet Invest. 1999; 47: 139-143.